This review is a product review of the use of Nivolumab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in patients progressing on or after platinum-based therapy.
The review discusses the evidence in support of the use of this approach, currently available treatments, the drugs’ pharmacology including mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Dr Venessa Chin, a medical oncologist at St Vincent’s Hospital Sydney, where she specialises in the treatment of patients with head and neck and lung cancer.
Please login below to download this issue (PDF)